Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP and SEFH
Calleja, Miguel Ángel
Álava, Enrique de
Lamas, María Jesús
MetadataShow full item record
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Precision medicine is transforming clinical and biomedical research, as well as health care itself from a conceptual,
as well as a methodological viewpoint, providing extraordinary opportunities to improve public health and lower the costs of the healthcare system. However, the implementation of precision medicine poses ethical-legal, regulatory, organizational and knowledge-related challenges. Without a national strategy, precision medicine, which will be implemented one way or another, could take place without the appropriate planning that can guarantee technical quality, equal access of all citizens to the best practices, violating the rights of patients and professionals and jeopardizing the solvency of the healthcare system. With this paper from the Spanish Societies of Medical Oncology (SEOM), Pathology (SEAP), and Hospital Pharmacy (SEFH) we highlight the need to institute a consensual national strategy for the development of precision medicine in our country, review the national and international context, comment on the opportunities and challenges for implementing precision medicine, and outline the objectives of a national strategy on precision medicine in cancer.
Is part ofFarmacia Hospitalaria, 2017, vol. 41, núm. 61, p. 688-691
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Garrido et al., 2017
Showing items related by title, author, creator and subject.
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels Llobet Navàs, David; Eritja Sánchez, Núria; Domingo, Mónica; Bergadà Bertran, Laura; Mirantes Barbeito, Cristina; Santacana Espasa, Maria; Pallares, Judit; Macià Armengol, Anna; Yeramian Hakim, Andree; Encinas Martín, Mario; Moreno-Bueno, Gema; Palacios, José; Lewis, Robert E.; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Elsevier Inc, 2011)The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway participates in many processes altered in development and progression of cancer in human beings such as proliferation, transformation, differentiation, and ...
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Alonso-Alconada, Lorena; Muinelo-Romay, Laura; Madissoo, Kadri; Díaz-López, Antonio; Krakstad, Camilla; Trovik, Jone; Wik, Elisabeth; Hapangama, Dharani; Coenegrachts, Lieve; Cano, Amparo; Gil-Moreno, Antonio; Chiva, Luís; Cueva, Juan; Vieito, María; Ortega Izquierdo, Maria Eugenia; Mariscal, Javier; Colas, Eva; Castellví, Josep; Cusido, Maite; Dolcet Roca, Xavier; Nijman, Hans W.; Bosse, Tjalling; Green, John A.; Romano, Andrea; Reventós, Jaume; López-López, Rafael; Salvesen, Helga B.; Amant, Frederic; Matias-Guiu, Xavier; Moreno-Bueno, Gema; Abal, Miguel (Biomed Central, 2014)Background: About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we ...
Grotsky, David A.; González-Suárez, Ignacio; Novell Álvarez, Anna; Neumann, Martin; Yaddanapudi, Sree C.; Croke, Monica; Martínez Alonso, Montserrat; Redwood, Abena B.; Ortega-Martinez, Sylvia; Feng, Zhihui; Lerma, Enrique; Ramon y Cajal, Teresa; Zhang, Junran; Matias-Guiu, Xavier; Dusso Rosso, Adriana; Gonzalo, Susana (The Rockefeller University Press, 2013)Loss of 53BP1 rescues BRCA1 deficiency and is associated with BRCA1-deficient and triple-negative breast cancers (TNBC) and with resistance to genotoxic drugs. The mechanisms responsible for decreased 53BP1 transcript ...